News
-
Dauntless Pharmaceutical has announced positive results from a Phase 1 trial of its DP1038 intranasal octreotide acetate, which it is developing for the treatment of acromegaly and neuroendocrine tumors. The company had announced initiation of… Read more . . .
-
Inhaled drug developer Pulmatrix has announced the appointment of former Sunovion Respiratory and CNS Business Unit Head Ted Raad as Chief Business Officer. Raad was most recently Chief Commercial Officer at Option Care, the home… Read more . . .
-
AstraZeneca will pay $45 million up front and up to $2.1 billion in milestone and commercial payments to Pieris Pharmaceuticals for development and commercialization rights to Pieris’s inhaled anticalin therapies, Pieris said. In the near… Read more . . .
-
Upsher Smith subsidiary Proximagen has announced that the Phase 3 ARTEMIS1 (Acute Rescue Therapy in Epilepsy with Midazolam Intranasal Spray) study of its USL261 intranasal midazolam for the treatment of seizure clusters, met its primary… Read more . . .
-
H&T Presspart has announced its acquisition of global rights to a capsule-based dry powder inhaler developed by Hovione. H&T Presspart will manufacture and commercialize the DPI, which will be marketed as PowdAir Plus. According to… Read more . . .
-
The US National Institutes of Health (NIH) has published two funding opportunity announcements (FOAs) related to nasal delivery of CNS therapeutics. The projects described in FOAs RFA-DA-18-006 and RFA-DA-18-007 are both supported by Small Business… Read more . . .
-
Digital health company Cohero Health has announced the appointment of Joe Condurso as CEO. Cohero and its partner Presspart introduced their eMDI smart inhaler system at DDL in 2016. Condurso was most recently CEO of… Read more . . .
-
Teva has launched both the AirDuo RespiClick fluticasone propionate/salmeterol DPI and an authorized generic version of the product in the US, the company said. The FDA approved 3 doses of AirDuo RespiClick for the treatment… Read more . . .
-
Invion has announced that Hong Kong based The Cho Group will acquire 15.03% of Invion for a total of A$656,682 through a private placement. A restructuring of Invion’s board will include the addition of two… Read more . . .
-
Arch Biopartners said that it has begun manufacturing clinical trial supplies for a Phase 1 study of its AB569 sodium nitrite/ethylenediaminetetraacetic acid (EDTA) inhalation solution for the treatment of antibiotic-resistant bacterial lung infections, and the… Read more . . .

Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
December 9-December 11: DDL 2026, Edinburgh, Scotland
April 27-30: RDD Europe 2027, Antibes, France
May 12-13: USP Joint Workshop: Quality and Product Performance Testing of Orally Inhaled and Nasal Drug Products, Rockville, MD, USA
May 30-June 2: ISAM Congress 2027, Dublin, Ireland
June 23: SMI London, London, UK


